Gemina Laboratories Ltd. (CSE: GLAB)

Market Cap	46.24M
Revenue (ttm)	n/a
Net Income (ttm)	-3.72M
Shares Out	74.57M
EPS (ttm)	-0.05
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	5,500
Open	0.630
Previous Close	0.650
Day's Range	0.615 - 0.650
52-Week Range	0.280 - 0.920
Beta	0.10
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 29, 2024

About Gemina Laboratories

Gemina Laboratories Ltd., a biotechnology company, engages in the research, development, and commercialization of in-vitro diagnostics in Canada. The company develops LEGIO X COVID-19, a COVID-19 rapid antigen test; and LEGIO X Influenza AB, an influenza AB multiplex lateral flow test. It is developing respiratory syncytial virus and tuberculosis. Gemina Laboratories Ltd. was incorporated in 2017 and is headquartered in Burnaby, Canada.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2017
• Employees: 6
• Stock Exchange: Canadian Securities Exchange
• Ticker Symbol: GLAB